BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2022 7:22:19 AM | Browse: 606 | Download: 1277
 |
Received |
|
2021-06-05 20:31 |
|
Peer-Review Started |
|
2021-06-05 20:35 |
|
First Decision by Editorial Office Director |
|
2021-07-27 06:26 |
|
Return for Revision |
|
2021-07-27 06:26 |
|
Revised |
|
2021-07-28 16:34 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-24 03:20 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-05-28 07:44 |
|
Articles in Press |
|
2022-05-28 07:44 |
|
Edit the Manuscript by Language Editor |
|
2022-05-22 02:13 |
|
Typeset the Manuscript |
|
2022-07-15 08:11 |
|
Publish the Manuscript Online |
|
2022-07-22 07:22 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tarun Sahu, Henu Kumar Verma and Bhaskar Lvks |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany. henu.verma@yahoo.com |
| Key Words |
COVID-19; Lymphoid malignancy; Lymphoma; Vaccination; Immunosuppression |
| Core Tip |
Patients with hematologic conditions are two times more likely than others to be admitted to the hospital. They are being treated with anti-cancer drugs, which weakens their immune system. As a result, these patients are always at risk of coronavirus disease 2019 (COVID-19). As we know, the COVID-19 is very lethal, and hematological malignancies are likely to increase the risk of negative outcomes from this viral infection. Currently, there are no guidelines for treating COVID-19 infected patients with hematological malignancies. |
| Publish Date |
2022-07-22 07:22 |
| Citation |
Sahu T, Verma HK, Lvks B. Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy. World J Virol 2022; 11(4): 204-207 |
| URL |
https://www.wjgnet.com/2220-3249/full/v11/i4/204.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v11.i4.204 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
